Annexon, Inc. (ANNX): Results of Operations and Financial Condition
Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-W
How this was made
The 30-second read
Why it matters
The filing provides time-specific regulatory and trial milestones (BLA expected in Q4 2026; Month 15 endpoint in Q4 2026; CAD POC update in Fall 2026) and a balance-sheet support item ($200M credit facility, $50M drawn at closing) that extends runway into 2028.
Market read
Traders can anchor positioning around the next disclosed decision points: Q4 2026 BLA submission and Month 15 endpoint readout, plus Fall 2026 CAD POC update.
What to watch
Credit facility details (terms, covenants, draw schedule) and the magnitude of dilution risk are not quantified here; investors may discount runway extension if financing terms are unfavorable.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon reported increased R&D and G&A expenses and a higher net loss, while strengthening liquidity through a credit facility and advancing several clinical and regulatory milestones.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development (R&D) expensesGAAP | $46.6 million | – | – |
| General and administrative (G&A) expensesGAAP | $10.6 million | – | – |
| Net loss attributable to common stockholdersGAAP | $55.3 million | – | – |
| Net loss per shareGAAP | $0.28 per share | – | – |
| Cash, cash equivalents and short-term investmentsother | $209.2 million | – | – |
into 2028 outlook
- NoteCash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.
- NoteBiologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.
- NoteMonth 15 primary endpoint on track for the fourth quarter of 2026.
- NoteFinal trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027.
- NoteUpdate on POC trial in CAD anticipated in the Fall of 2026.
What drove it
- R&D expense change was primarily associated with the Phase 3 ARCHER II trial of vonaprument in GA and contract manufacturing expenses of product candidates.
- G&A expense change reflected ongoing corporate consulting and professional services costs for advancement of registrational programs.
- Early improvement in strength and clinically meaningful reduction in disability were reported in the first ten U.S. and European patients with GBS from the ongoing open-label FORWARD study.
- The EU Marketing Authorisation Application for tanruprubart is under review with the European Medicines Agency.
- All eligible patients in the global Phase 3 ARCHER II trial have received at least 12 months of treatment, with masked event accrual consistent with projected timelines.
- Vonaprument was described as generally well-tolerated, with a low discontinuation rate (<10%) and high compliance (>95%).
Concerns
- Net loss attributable to common stockholders was $55.3 million, compared to $49.2 million for the quarter ended June 30, 2025.
- R&D expenses were $46.6 million, compared to $44.2 million for the quarter ended June 30, 2025.
- G&A expenses were $10.6 million, compared to $7.6 million for the quarter ended June 30, 2025.
- The BLA submission, ARCHER II primary-endpoint results, and ANX1502 proof-of-concept update remain anticipated future milestones rather than reported outcomes.
- The company cited risks including final Phase 3 ARCHER II results, ability to obtain necessary capital, potential clinical-trial delays, regulatory acceptance of clinical data, and ability to obtain regulatory approval and commercialize product candidates.
What to watch
- Biologics License Application submission with U.S./European data from the FORWARD trial expected in fourth quarter of 2026.
- Month 15 primary endpoint from the Phase 3 ARCHER II trial on track for the fourth quarter of 2026.
- ANX1502 proof-of-concept trial update in cold agglutinin disease anticipated in the Fall of 2026.
- Final ARCHER II trial completion, including the Month 24 primary endpoint, expected in the third quarter of 2027.
- Execution against the stated operating runway into 2028 following the initial draw under the credit facility.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026.
- Entered into a strategic credit facility of up to $200 million with Oxford Finance LLC.
- Initial $50 million drawn at closing.
- Current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.
Analysis
Annexon remains a clinical-stage company in an execution-heavy period, with the quarter defined by pipeline milestones rather than reported commercial revenue. The company highlighted early strength improvement and clinically meaningful disability reduction in the first ten U.S. and European patients in the open-label FORWARD GBS study. Its EU Marketing Authorisation Application is under review, and it expects a BLA submission supported by U.S./European FORWARD data in the fourth quarter of 2026.
Investment in the pipeline increased. R&D expenses were $46.6 million, compared to $44.2 million for the quarter ended June 30, 2025, primarily tied to the Phase 3 ARCHER II trial of vonaprument and contract manufacturing. G&A expenses were $10.6 million, compared to $7.6 million, reflecting corporate consulting and professional services supporting registrational programs. Net loss attributable to common stockholders was $55.3 million, compared to $49.2 million.
The GA program added strategic scope during the quarter. ARCHER II retained its Month 15 primary endpoint while adding a Month 24 dual primary endpoint, allowing success at either independent efficacy timepoint. All eligible patients have received at least 12 months of treatment, and the company said masked event accrual remains consistent with projected timelines. The Month 15 endpoint is on track for the fourth quarter of 2026, while final completion including the Month 24 endpoint is expected in the third quarter of 2027. Annexon also launched an open-label extension study for longer-term safety and benefit evaluation.
Liquidity is a central positive offset to the operating loss. Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026. The company also entered a credit facility of up to $200 million, with an initial $50 million drawn at closing, and stated that current liquidity plus credit-facility funds are expected to fund operations and anticipated milestones into 2028. No prior-quarter financial comparison was reported, so quarter-over-quarter changes in expenses, loss, and liquidity cannot be assessed from the filing.
The near-term read is therefore driven by clinical and regulatory execution. Investors will focus on the expected fourth-quarter 2026 BLA submission for tanruprubart, the ARCHER II Month 15 primary endpoint, and the Fall 2026 ANX1502 proof-of-concept update. The release did not report topline efficacy data from ARCHER II, nor did it provide financial revenue or expense guidance beyond the stated runway.
Management, verbatim
2026 is a defining year for our company, with meaningful progress across both our Guillain-Barré syndrome (GBS) and geographic atrophy (GA) programs that position us to potentially deliver two transformative therapies for millions of patients in need.
Douglas Love, president and chief executive officer of Annexon
With our leadership capabilities and financial position strengthened, we are entering an exciting period of execution, with multiple important clinical and regulatory milestones expected over the next 6 to 12 months and a significant opportunity to create value for patients and stakeholders.
Douglas Love, president and chief executive officer of Annexon
Not in the filing
stated, not guessed- Total revenue and prior-year, prior-quarter, year-over-year, and quarter-over-quarter revenue comparisons were not reported in the provided text.
- Segment revenue and segment growth comparisons were not reported.
- Gross profit, gross margin, operating income or loss, and operating margin were not reported in the provided text.
- Non-GAAP financial measures were not reported.
- Operating cash flow, free cash flow, capital expenditures, and cash-flow comparisons were not reported.
- Debt balance, interest expense, and repayment terms were not reported. The filing reported only a credit facility of up to $200 million and an initial $50 million draw.
- Share repurchases, dividends, and other capital-return activity were not reported.
- Prior-quarter figures and quarter-over-quarter changes for R&D expenses, G&A expenses, net loss, net loss per share, and cash were not reported.
- Year-over-year percentage changes for R&D expenses, G&A expenses, net loss, and net loss per share were not reported.
- Financial revenue, gross-margin, operating-expense, and tax-rate guidance were not reported.
- Prior-quarter outlook was not provided, so comparison of actual results with prior guidance was not available.
- The filing text was truncated before the condensed consolidated statements of operations tables, so any additional line items in those tables were not available for verification.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with Annexon’s Q2 2026 financial results plus portfolio milestone updates across tanruprubart (GBS), vonaprument (GA), and ANX1502 (CAD).
Ticker impact
Annexon reported Q2 2026 results and reiterated key clinical/regulatory milestones, including expected Q4 2026 BLA submission for tanruprubart.
Moderate upside bias into the next milestone windows, with volatility around any trial/endpoint updates and BLA progress.
The filing is a primary disclosure with multiple time-stamped catalysts (Q4 2026 BLA, Q4 2026 Month 15 endpoint, Fall 2026 POC update) and a balance-sheet support item (credit facility, runway into 2028).
Market effects
Reinforces investor appetite for C1q-targeted neuroinflammation programs and the market’s focus on fast-acting complement therapeutics.
Limited direct regional spillover; primarily affects US-listed biotech sentiment and European regulatory-readiness expectations.
Global relevance via EU/EMA review and worldwide patient burden framing, but the tradable catalyst is company-specific timing.
Counterpoint
Clinical “on track” language and early patient outcomes may not translate into regulatory-grade efficacy; the dual-endpoint strategy can also increase interpretation risk.
Key entities
- issuerAnnexon, Inc.
Nasdaq-listed biopharmaceutical company advancing C1q-targeted immunotherapies for neuroinflammatory diseases.
- credit_facility_counterpartyOxford Finance LLC
Counterparty for Annexon’s strategic credit facility of up to $200 million.
- regulatorEuropean Medicines Agency (EMA)
Regulatory body supporting the EU marketing authorization application under review for tanruprubart.
